Researchers at the National Institutes of Health (NIH) have peered deep inside the brain cells of mice to figure out why blockbuster weight loss drugs like Ozempic and Wegovy eventually stop working as well as they used to. Spoiler alert: it's not because you cheated on your diet.
The findings, based on experiments in mice led by first author Claire Gao, Ph.D., a postdoctoral fellow at NIH's National Institute of General Medical Sciences (NIGMS), reveal that the drug semaglutide - the active ingredient in both Ozempic and Wegovy - triggers a rise in a signaling molecule called cyclic adenosine monophosphate (cAMP) in a brain region known as the area postrema, which handles appetite regulation. But here's the kicker: not all neurons respond equally.
"It was not an all or nothing phenomenon. We observed that cAMP responses across cells varied on a continuum," said co-corresponding author Michael Krashes, Ph.D., a senior investigator at NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). In plain English: some neurons kept the cAMP party going for a long time, while others called it quits early by internalizing or breaking down GLP-1 receptors.
The research team, led by co-corresponding author Andrew Lutas, Ph.D., an investigator at NIDDK, used fluorescence imaging to watch semaglutide work its magic on living mouse brain tissue. By blocking or removing specific signaling molecules inside neurons, they pinpointed which cellular pathways mattered most for weight loss.
But wait - there's hope for those hitting a plateau. The team tested whether they could prolong these signals by using the drug roflumilast to block PDE4, an enzyme that chews up cAMP. The result? More neurons switched to the longer-lasting response mode. This raises the possibility that future GLP-1 treatments could remain effective for longer, potentially reducing how often patients need injections and helping people overcome those dreaded weight loss plateaus.
Of course, the researchers caution that much more study is needed before anyone starts celebrating. One limitation: they could only observe intracellular signaling in brain tissue for a few hours at a time. The team hopes to use newer techniques in future studies to track how GLP-1 drugs affect neurons over days or even weeks.
In the meantime, the findings offer a deeper look into the brain chemistry behind GLP-1 medications and may help guide the development of more effective weight loss treatments - assuming, of course, your neurons don't get bored again.